Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00500110
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00388804
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 706
- Registration Number
- NCT00378690
Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 91
- Registration Number
- NCT00355030
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands
Melanoma Vaccine With Peptides and Leuprolide
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT00254397
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Schiffler Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00243646
- Locations
- 🇺🇸
Seattle Prostate Institute, Seattle, Washington, United States
🇺🇸Groupe Health Cooperative, Veterans Adminstration Hospital and University of Washington, Seattle, Washington, United States
🇺🇸Schiffler Cancer Center, Wheeling, West Virginia, United States
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 1071
- Registration Number
- NCT00193856
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺St George Hospital, Kogarah, New South Wales, Australia
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 2028
- Registration Number
- NCT00002597
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 45
- Registration Number
- NCT00004763
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.